# BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis

> **NCT00095173** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 214 (actual)

## Conditions studied

- Juvenile Rheumatoid Arthritis

## Interventions

- **DRUG:** Abatacept
- **DRUG:** Placebo
- **DRUG:** Abatacept

## Key facts

- **NCT ID:** NCT00095173
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2006-06
- **Final completion:** 2011-11
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095173, "BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00095173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*